

# International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,<sup>1</sup> notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, e.g., for List 61 Prop. INN not later than 30 November 1989.

*The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.*

## Action and Use

The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded proposed INNs. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature these descriptors will not be included in the Cumulative Lists of INNs.

## Proposed International Nonproprietary Names (Prop. INN): List 61<sup>2</sup>

Comprehensive information on the INN programme can be found in: WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances*, Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4 (price: Sw. fr. 6.-); an account of this publication will be found in Annex 2 of the present List. All names from: Lists 1-47 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in: *International Nonproprietary Names (INN) for Pharmaceutical Substances, Cumulative List No. 7*, 1988, World Health Organization, Geneva (ISBN 92 4 056014 9) (price: Sw. fr. 65.-). This publication consists, in the main, of a computer printout which groups together all the proposed and recommended international nonproprietary names (INN)—in Latin, English, French, Russian, and Spanish—published up to March 1988. The printout also indicates in which of the 58 individual lists of proposed names and 27 lists of recommended names each INN was originally published, and gives references to national nonproprietary names, pharmacopoeia monographs, and other sources. In addition, the list contains molecular formulae and Chemical Abstracts Service registry numbers. For easy reference, national nonproprietary names that differ from INN, molecular formulae, and Chemical Abstracts Service registry numbers are indexed in a series of annexes. A final annex describes the procedure for selecting recommended INN and outlines the general principles to be followed in devising these names. All the textual material published in this volume appears in both English and French.

These publications may be obtained, direct or through booksellers, from the sales agents listed on the back cover of *WHO Drug Information*. Orders from countries where sales agents have not yet been appointed may be addressed to: World Health Organization, Distribution and Sales Service, 1211 Geneva 27, Switzerland.

<sup>1</sup> Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.*, 1955, **60**, 3) and amended by the Board in resolution EB43.R9 (*Off. Rec. Wld Hlth Org.*, 1969, **173**, 10).


<sup>2</sup> Other lists of proposed and recommended international nonproprietary names can be found in *Cumulative List No. 7*, 1988.

Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


ablukastum  
ablukast

(±)-6-acetyl-7-[[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl]oxy]-  
2-chromancarboxylic acid  
C<sub>28</sub>H<sub>34</sub>O<sub>8</sub> 96566-25-5 *antiallergic, antiasthmatic*




acamprosatum  
acamprosate  
6473

3-acetamido-1-propanesulfonic acid  
C<sub>5</sub>H<sub>11</sub>NO<sub>4</sub>S 77337-76-9 *psychotropic*




acidum alendronicum  
alendronic acid

(4-amino-1-hydroxybutylidene)diphosphonic acid  
C<sub>4</sub>H<sub>13</sub>NO<sub>7</sub>P<sub>2</sub> 66376-36-1 *Calcium regulator*




acidum neridronicum  
neridronic acid

(6-amino-1-hydroxyhexylidene)diphosphonic acid  
C<sub>6</sub>H<sub>17</sub>NO<sub>7</sub>P<sub>2</sub> 79778-41-9 *Calcium regulator*




altoqualinum  
altoqualine

(3*S*)-7-amino-4,5,6-triethoxy-3-[(1*R*)-1,2,3,4-tetrahydro-6,7,8-trimethoxy-2-methyl-1-isoquinoly]phthalide  
 $C_{27}H_{36}N_2O_8$  121029-11-6 *antiallergic, antihistaminic*




amocarzinum  
amocarzine

4-methyl-4'-(*p*-nitroanilino)thio-1-piperazinecarboxanilide  
 $C_{18}H_{21}N_5O_2S$  36590-19-9 *antifilarial*




artemetherum  
artemether

(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*S*,12*R*,12*aR*)-decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12*H*-pyrano[4,3-*j*]-1,2-benzodioxepin  
 $C_{16}H_{26}O_5$  71963-77-4 *antimalarial*




artesunatum  
artesunate

(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*S*,12*R*,12*aR*)-decahydro-3,6,9-trimethyl-3,12-epoxy-12*H*-pyrano[4,3-*j*]-1,2-benzodioxepin-10-ol, hydrogen succinate  
 $C_{19}H_{28}O_8$  88495-63-0 *antimalarial*




atrimustinum  
atrimustine

estradiol 3-benzoate 17-glycolate, 4-[*p*-[bis(2-chloroethyl)amino]phenyl]butyrate  
C<sub>41</sub>H<sub>47</sub>Cl<sub>2</sub>NO<sub>6</sub> 75219-46-4 *antineoplastic*




avobenzonum  
avobenzone

1-(*p*-*tert*-butylphenyl)-3-(*p*-methoxyphenyl)-1,3-propanedione  
C<sub>20</sub>H<sub>22</sub>O<sub>3</sub> 70356-09-1 *sunscreens*




bakeprofenum  
bakeprofen

(±)-2-(*m*-benzoylphenoxy)propionic acid  
C<sub>16</sub>H<sub>14</sub>O<sub>4</sub> 74168-02-8 *analgesic, nonsteroidal anti-inflammatory*




batanopridum  
batanopride

(±)-4-amino-5-chloro-*N*-[2-(diethylamino)ethyl]-2-[(1-methylacetyl)oxy]-benzamide  
C<sub>17</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>3</sub> 102670-46-2 *antiemetic*




belfosdilum  
belfosdil

tetrabutyl [2-(2-phenoxyethyl)trimethylene]diphosphonate  
C<sub>27</sub>H<sub>50</sub>O<sub>7</sub>P<sub>2</sub> 103486-79-9 *Calcium antagonist*




bemoradanum  
bemoradan

(±)-7-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one  
C<sub>13</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub> 112018-01-6 *positive inotropic agent*




calcipotriolum.  
calcipotriol

(5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1 $\alpha$ ,3 $\beta$ ,24-triol  
C<sub>27</sub>H<sub>40</sub>O<sub>3</sub> 112828-00-9 *antipsoriatic*




camonagrelum  
camonagrel

(±)-5-(2-imidazol-1-ylethoxy)-1-indancarboxylic acid  
C<sub>15</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> 105920-77-2 *platelet aggregation inhibitor*




carboxirolum  
carboxirole

3-[4-(3,6-dihydro-4-phenyl-1(2H)-pyridyl)butyl]indole-5-carboxylic acid  
C<sub>24</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub> 98323-83-2 *D<sub>1</sub>-dopamine receptor agonist*




cefdinirum  
cefdinir

(-)-(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7<sup>2</sup>-(*Z*)-oxime  
C<sub>14</sub>H<sub>13</sub>N<sub>5</sub>O<sub>5</sub>S<sub>2</sub> 91832-40-5 antibiotic




cilutazolinum  
cilutazoline

2-[[[(6-cyclopropyl-*m*-tolyl)oxy]methyl]-2-imidazoline  
C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O 104902-08-1 nasal vasoconstrictor




clentiazemum  
clentiazem

(+)-*cis*-8-chloro-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(*p*-methoxyphenyl)-1,5-benzothiazepin-4(5*H*)-one acetate (ester)  
C<sub>22</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>4</sub>S 96125-53-0 Calcium antagonist




cronidipinum  
cronidipine

[8-(*p*-chlorophenyl)-1,4-dioxo-8-azaspiro[4,5]dec-2-yl]methyl methyl  
1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate  
C<sub>30</sub>H<sub>32</sub>ClN<sub>3</sub>O<sub>8</sub> 113759-50-5 Calcium antagonist




danofloxacinum  
danofloxacin

1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(1*S*,4*S*)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4-oxo-3-quinolinecarboxylic acid  
C<sub>19</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>3</sub> 112398-08-0 *antibacterial (vet.)*




decitabinum  
decitabine

4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1*H*)-one  
C<sub>8</sub>H<sub>12</sub>N<sub>4</sub>O<sub>4</sub> 2353-33-5 *antineoplastic*




deslorelinum  
deslorelin

5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide  
C<sub>64</sub>H<sub>83</sub>N<sub>17</sub>O<sub>12</sub> 57773-65-6 *LHRH analogue*




dexibuprofenum  
dexibuprofen

(*S*)-(+)-*p*-isobutylhydratropic acid  
C<sub>13</sub>H<sub>18</sub>O<sub>2</sub> 51146-56-6 *analgesic, nonsteroidal anti-inflammatory*



divaplonum  
divaplon

6-ethyl-7-methoxy-5-methylimidazo[1,2-*a*]pyrimidin-2-yl phenyl ketone  
C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> 90808-12-1 *anxiolytic*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


docebenonum  
docebenone

2-(12-hydroxy-5,10-dodecadiynyl)-3,5,6-trimethyl-*p*-benzoquinone  
 $C_{21}H_{26}O_3$  80809-81-0 *antiallergic, antiasthmatic*




doconexentum  
doconexent

(*all-Z*)-4,7,10,13,16,19-docosahexaenoic acid  
 $C_{22}H_{32}O_2$  6217-54-5 *platelet aggregation inhibitor*




ecomustinum  
ecomustine

methyl 3-[3-(2-chloroethyl)-3-nitrosoureido]-2,3-dideoxy- $\alpha$ -D-*arabino*-  
hexopyranoside  
 $C_{10}H_{18}ClN_3O_6$  98383-18-7 *antineoplastic*




edatrexatum  
edatrexate

*N*-[*p*-[1-[(2,4-diamino-6-pteridiny)methyl]propyl]benzoyl]-L-glutamic acid  
 $C_{22}H_{25}N_7O_5$  80576-83-6 *antineoplastic*




eflumastum  
eflumast

3'-acetyl-5'-fluoro-2'-hydroxy-1*H*-tetrazole-5-carboxanilide  
 $C_{10}H_8FN_5O_3$  70977-46-7 *antiallergic, antiasthmatic*




elgodipinum  
elgodipine

2-[(*p*-fluorobenzyl)methylamino]ethyl isopropyl (±)-1,4-dihydro-2,6-dimethyl-4-[2,3-(methylenedioxy)phenyl]-3,5-pyridinedicarboxylate  
C<sub>29</sub>H<sub>33</sub>FN<sub>2</sub>O<sub>6</sub> 119413-55-7 Calcium antagonist




emonapridum  
emonapride

(±)-*cis*-*N*-(1-benzyl-2-methyl-3-pyrrolidiny)-5-chloro-4-(methylamino)-*o*-anisamide  
C<sub>21</sub>H<sub>26</sub>ClN<sub>3</sub>O<sub>2</sub> 93664-94-9 D<sub>1</sub>-dopamine receptor antagonist




enalkirenum  
enalkiren

(*αS*)-*α*-[(*αS*)-*α*-(3-amino-3-methylbutyramido)-*p*-methoxyhydrocinnamamido]-*N*-[(1*S*,2*R*,3*S*)-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]imidazole-4-propionamide  
C<sub>35</sub>H<sub>56</sub>N<sub>6</sub>O<sub>6</sub> 113082-98-7 renin inhibitor




epervudinum  
epervudine

2'-deoxy-5-isopropyluridine  
C<sub>12</sub>H<sub>18</sub>N<sub>2</sub>O<sub>5</sub> 60136-25-6 antiviral




famciclovir  
famciclovir

2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate (ester)  
C<sub>14</sub>H<sub>19</sub>N<sub>5</sub>O<sub>4</sub> 104227-87-4 *antiviral*



faspionum  
faspion

6-ethyl-7-methoxy-5-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo-  
[1,2-a]pyrimidine  
C<sub>13</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub> 106100-65-6 *anxiolytic*




fibrinum  
fibrin

an insoluble plasma protein obtained by the action of thrombin on  
fibrinogen. The source of the product should be indicated, e.g. fibrin  
(bovine).

*local haemostatic agent*


fludeoxyglucosum (<sup>18</sup>F)  
fludeoxyglucose (<sup>18</sup>F)

2-deoxy-2-fluoro-<sup>18</sup>F- $\alpha$ -D-glucopyranose  
C<sub>6</sub>H<sub>11</sub><sup>18</sup>FO<sub>5</sub> 105851-17-0 *radioactive diagnostic agent*




flutomidatum  
flutomidate

ethyl ( $\pm$ )-1-(p-fluoro- $\alpha$ -methylbenzyl)imidazole-5-carboxylate  
C<sub>14</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>2</sub> 84962-75-4 *anaesthetic (vet.)*




flutrimazolium  
flutrimazole

1-[o-fluoro- $\alpha$ -(p-fluorophenyl)- $\alpha$ -phenylbenzyl]imidazole  
C<sub>22</sub>H<sub>16</sub>F<sub>2</sub>N<sub>2</sub> 119006-77-8 *antifungal*




galamustinum  
galamustine

6-[bis(2-chloroethyl)amino]-6-deoxy- $\beta$ -galactopyranose  
C<sub>10</sub>H<sub>19</sub>Cl<sub>2</sub>NO<sub>5</sub> 105618-02-8 *antineoplastic*




gedocarnilum  
gedocarnil

isopropyl 5-(*p*-chlorophenoxy)-4-(methoxymethyl)-9*H*-pyrido[3,4-*b*]indole-3-carboxylate  
C<sub>23</sub>H<sub>21</sub>ClN<sub>2</sub>O<sub>4</sub> 109623-97-4 *partial benzodiazepine receptor agonist*




gevotrolinum  
gevotroline

8-fluoro-2,3,4,5-tetrahydro-2-[3-(3-pyridyl)propyl]-1*H*-pyrido[4,3-*b*]indole  
C<sub>19</sub>H<sub>20</sub>FN<sub>3</sub> 107266-06-8 *antipsychotic*




icosapentum  
icosapent

(*all-Z*)-5,8,11,14,17-icosapentaenoic acid or (*all-Z*)-5,8,11,14,17-icosapentaenoic acid  
C<sub>20</sub>H<sub>30</sub>O<sub>2</sub> 10417-94-4 *platelet aggregation inhibitor*




isaglidolum  
isaglidole

4-fluoro-2-(2-imidazolylamino)isoindoline  
C<sub>11</sub>H<sub>13</sub>FN<sub>4</sub> 110605-64-6 *antidiabetic*




isosorbidum  
isosorbide

1,4:3,6-dianhydro-D-glucitol  
C<sub>6</sub>H<sub>10</sub>O<sub>4</sub> 652-67-5




lactolum  
lactitol

4-O-β-D-galactopyranosyl-D-glucitol  
C<sub>12</sub>H<sub>24</sub>O<sub>11</sub> 585-86-4 *sweetener*




laidlomycinum  
laidlomycin

(αS,βR,γS,2S,5R,7S,8R,9S)-β,9-dihydroxy-α,γ,2,8-tetramethyl-2-[(2R,5S)-tetrahydro-5-methyl-5-[(2R,3S,5R)-tetrahydro-3-methyl-5-[(2S,3S,5R,6R)-tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl]-2-furyl]-1,6-dioxaspiro[4.5]decane-7-butyrac acid, β-propionate  
C<sub>37</sub>H<sub>62</sub>O<sub>12</sub> 56283-74-0 *coccidiostatic (vet.)*




letrazurilum  
letrazuril

(±)-[2,6-dichloro-4-(4,5-dihydro-3,5-dioxo-as-triazin-2(3H)-yl)phenyl](p-fluorophenyl)acetonitrile  
C<sub>17</sub>H<sub>9</sub>Cl<sub>2</sub>FN<sub>4</sub>O<sub>2</sub> 103337-74-2 *coccidiostatic (vet.)*



levobetaxololum  
levobetaxolol

(-)-(S)-1-[p-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol  
C<sub>18</sub>H<sub>29</sub>NO<sub>3</sub> 93221-48-8 *β-adrenoreceptor antagonist*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


losigamonum  
losigamone

(5*R*\*)-5-[(*αS*\*)-*o*-chloro-*α*-hydroxybenzyl]-4-methoxy-2(5*H*)-furanone  
C<sub>12</sub>H<sub>11</sub>ClO<sub>4</sub> 112856-44-7 *antiepileptic*




losmiprofenum  
losmiprofen

(±)-2-[[3-(*p*-chlorobenzoyl)-*o*-tolyl]oxy]propionic acid  
C<sub>17</sub>H<sub>15</sub>ClO<sub>4</sub> 74168-08-4 *nonsteroidal anti-inflammatory*




miltefosinum  
miltefosine

choline hydroxide, hexadecyl hydrogen phosphate, inner salt  
C<sub>21</sub>H<sub>46</sub>NO<sub>4</sub>P 58066-85-6 *antineoplastic*




mirtazapinum  
mirtazapine

1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine  
C<sub>17</sub>H<sub>13</sub>N<sub>3</sub> 61337-67-5 *antidepressant*




moguisteinum  
moguisteine

ethyl (±)-2-[(*o*-methoxyphenoxy)methyl]-β-oxo-3-thiazolidinepropionate  
C<sub>16</sub>H<sub>21</sub>NO<sub>5</sub>S 119637-67-1 *antitussive*




moxidectinum  
moxidectin

(6*R*,25*S*)-5-*O*-demethyl-28-deoxy-25-[(*E*)-1,3-dimethyl-1-butenyl]-6,28-epoxy-23-oxomilbemycin B 23-(*O*-methyloxime)  
C<sub>37</sub>H<sub>53</sub>NO<sub>8</sub> 113507-06-5 antiparasitic (vet.)




natrii borocaptas (<sup>10</sup>B)  
sodium borocaptate (<sup>10</sup>B)

disodium undecahydromercaptododecaborate(2-)-<sup>10</sup>B<sub>12</sub>  
Na<sub>2</sub><sup>10</sup>B<sub>12</sub>H<sub>12</sub>S 103831-41-0 neutron capture agent




ocfentanilum  
ocfentanil

2'-fluoro-2-methoxy-*N*-(1-phenethyl-4-piperidyl)acetanilide  
C<sub>22</sub>H<sub>27</sub>FN<sub>2</sub>O<sub>2</sub> 101343-69-5 narcotic analgesic




pemirolastum  
pemirolast

9-methyl-3-(1*H*-tetrazol-5-yl)-4*H*-pyrido[1,2-*a*]pyrimidin-4-one  
C<sub>10</sub>H<sub>8</sub>N<sub>6</sub>O 69372-19-6 antiallergic




penciclovirum  
penciclovir

9-[4-hydroxy-3-(hydroxymethyl)butyl]guanine  
 $C_{10}H_{15}N_5O_3$  39809-25-1 *antiviral*




pidolacetamolum  
pidolacetamol

5-oxo-L-proline, ester with 4'-hydroxyacetanilide  
 $C_{13}H_{14}N_2O_4$  114485-92-6 *analgesic, antipyretic*




rebamipidum  
rebamipide

(±)-a-(p-chlorobenzamido)-1,2-dihydro-2-oxo-4-quinolinepropionic acid  
 $C_{19}H_{15}ClN_2O_4$  111911-87-6 *antiulcer*




revospironum  
revospirone

2-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]-1,2-benzisothiazolin-3-one  
1,1-dioxide  
 $C_{18}H_{21}N_5O_3S$  95847-87-3 *tranquillizer (vet.)*




rifametanum  
rifametanone

(2*S*,12*Z*,14*E*,16*S*,17*S*,18*R*,19*R*,20*R*,21*S*,22*S*,23*S*,24*E*)-1,2-dihydro-5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-*b*]furan-8-carboxaldehyde, 8-azine with *N,N*-diethylacetamide, 21-acetate  
C<sub>44</sub>H<sub>60</sub>N<sub>4</sub>O<sub>12</sub> 94168-98-6 antibiotic




romurtidum  
romurtide

2-acetamido-3-*O*-[*(R)*-1-[[*(S)*-1-[[*(R)*-1-carbamoyl-3-[[*(S)*-1-carboxy-5-stearamidopentyl]carbamoyl]propyl]carbamoyl]ethyl]carbamoyl]ethyl]-2-deoxy- $\beta$ -D-glucopyranose  
C<sub>43</sub>H<sub>78</sub>N<sub>6</sub>O<sub>13</sub> 78113-36-7 immunomodulator




ropinirolum  
ropinirole

4-[2-(dipropylamino)ethyl]-2-indolinone  
C<sub>16</sub>H<sub>24</sub>N<sub>2</sub>O 91374-21-9 D<sub>2</sub>-dopamine receptor agonist




sertindolum  
sertindole

1-[2-[4-[5-chloro-1-(*p*-fluorophenyl)indol-3-yl]piperidino]ethyl]-2-imidazolidinone  
C<sub>24</sub>H<sub>26</sub>ClFN<sub>4</sub>O 106516-24-9 antipsychotic




suronacrinum  
suronacrine

(±)-9-(benzylamino)-1,2,3,4-tetrahydro-1-acridinol  
C<sub>20</sub>H<sub>20</sub>N<sub>2</sub>O 104675-35-6 *cholinesterase inhibitor*




taludipinum  
taludipine

(±)-4-[o-[(E)-2-carboxyvinyl]phenyl]-2-[(dimethylamino)methyl]-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid, 4-*tert*-butyl diethyl ester  
C<sub>28</sub>H<sub>38</sub>N<sub>2</sub>O<sub>6</sub> 108687-08-7 *Calcium antagonist*




taniplonum  
taniplon

6,7,8,9-tetrahydro-5-methoxy-2-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo-[1,2-a]quinazoline  
C<sub>14</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub> 106073-01-2 *anxiolytic*



technetium (<sup>99m</sup>Tc) teboroximum  
technetium (<sup>99m</sup>Tc) teboroxime

[bis[(1,2-cyclohexanedione dioximato)(1)-O][[(1,2-cyclohexanedione dioximato)(2)-O]methylborato(2-)-N,N',N'',N''',N'''']chloro[<sup>99m</sup>Tc]technetium(III)  
C<sub>19</sub>H<sub>29</sub>BClN<sub>6</sub>O<sub>6</sub> <sup>99m</sup>Tc 104716-22-5 *radioactive diagnostic agent*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


tenidapum  
tenidap

(±)-5-chloro-2-oxo-3-(2-thenoyl)-1-indolinecarboxamide  
C<sub>14</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>3</sub>S 100599-27-7 *nonsteroidal anti-inflammatory*




terflavoxatum  
terflavoxate

1,1-dimethyl-2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate  
C<sub>26</sub>H<sub>29</sub>NO<sub>4</sub> 86433-40-1 *antispasmodic*




thymotrivanum  
thymotrivan

*N*-(*N*<sup>2</sup>-L-arginyl-L-lysyl)-L-aspartic acid  
C<sub>16</sub>H<sub>31</sub>N<sub>7</sub>O<sub>6</sub> 85465-82-3 *immunomodulator*



toripristonum  
toripristone

17β-hydroxy-11β-[*p*-(isopropylmethylamino)phenyl]-17-(1-propynyl)estra-4,9-dien-3-one  
C<sub>31</sub>H<sub>39</sub>NO<sub>2</sub> 91935-26-1 *antiglucocorticoid*




Proposed International  
Nonproprietary Name (Latin, English)

Chemical Name or Description, Molecular and Graphic Formulae  
Chemical Abstracts Service (CAS) registry number  
Action and use


troquidazolium  
troquidazole

*N*-(3-nitro-4-quinolyl)-4-morpholinecarboxamide  
 $C_{14}H_{13}N_5O_3$  108001-60-1 *radiosensitizing agent*




velnacrinum  
velnacrine

(±)-9-amino-1,2,3,4-tetrahydro-1-acridinol  
 $C_{13}H_{14}N_2O$  112964-98-4 *cholinesterase inhibitor*




vintoperolum  
vintoperol

(-)-(1*S*,12*bS*)-1-ethyl-1,2,3,4,6,7,12,12*b*-octahydroindolo[2,3-*a*]quinolizine-  
1-methanol  
 $C_{18}H_{24}N_2O$  106498-99-1 *peripheral vasodilator*



voxergolidum  
voxergolide

(±)-(6*aR*,9*R*,10*aR*)-4,6*a*,7,8,9,10*a*-hexahydro-7-methyl-9-[(methylthio)methyl]-  
6*H*-indolo[3,4-*gh*][1,4]benzoxazine  
 $C_{16}H_{20}N_2OS$  89651-00-3 *dopamine receptor agonist*



## Names for Radicals and Groups

Some substances for which a proposed international non-proprietary name has been established may be used in the form of salts or esters. The radicals or groups involved

may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals


and groups have been devised or selected, and they are suggested for use with the proposed international non-proprietary names.

butepras  
buteprate

butyrate propionate


crobefas  
crobefate

(±)-(E)-6-hydroxy-4'-methoxy-3-(p-methoxybenzylidene)flavanone,  
phosphate, ion(2-)  
C<sub>24</sub>H<sub>19</sub>O<sub>8</sub> P



farnesilum  
farnesil

(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl  
C<sub>15</sub>H<sub>25</sub>



**AMENDMENTS  
TO PREVIOUS LISTS**

WHO Chronicle, Vol. 36, No. 5, 1982


**Proposed International Nonproprietary Names (Prop. INN): List 48**

p. 13	<i>delete</i>	<i>insert</i>
	loxtidinum	lavoltidinum
	loxtidine	lavoltidine

WHO Chronicle Vol. 37, No. 5, 1983

**Proposed International Nonproprietary Names (Prop. INN): List 50**


p. 17	levocabastinum levocabastine	<i>replace the chemical name and the graphical formula by:</i> (-)-(3 <i>S</i> ,4 <i>R</i> )-1-[ <i>cis</i> -4-cyano-4-( <i>p</i> -fluorophenyl)cyclohexyl]-3-methyl-4-phenylisonipecotic acid
-------	---------------------------------	---



WHO Drug Information Vol. 1, No. 3, 1987

**Proposed International Nonproprietary Names (Prop. INN): List 58**

p. 186	pemedolacum pemedolac	<i>replace the chemical name, the CAS registry number and the graphic formula by the following:</i> (±)- <i>cis</i> -4-benzyl-1-ethyl-1,3,4,9-tetrahydropyrano[3,4- <i>b</i> ]indole-1-acetic acid 114716-16-4
--------	--------------------------	--




WHO Drug Information Vol. 2, No. 4, 1988

**Proposed International Nonproprietary Names (Prop. INN): List 60**

p. 4	<i>delete</i>	<i>insert</i>
	mequitazii iodidum	mequitamii iodidum
	mequitazium iodide	mequitamium iodide

p. 6	cefprozilum cefprozil	<i>replace the chemical name and the graphical formula by the following:</i> (6 <i>R</i> ,7 <i>R</i> )-7-[( <i>R</i> )-2-amino-2-( <i>p</i> -hydroxyphenyl)acetamido]-8-oxo-3-propenyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid.
------	--------------------------	--



**Annex 1**  
**PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL  
NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES\***

The following procedure shall be followed by the World Health Organization in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with the World Health Assembly resolution WHA3.11:

1. Proposals for recommended international nonproprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the "General principles for guidance in devising International Nonproprietary Names", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international nonproprietary name is being considered.

A. Such notice shall be given by publication in the *Chronicle of the World Health Organization*<sup>1</sup> and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

- (i) Notice may also be sent to specific persons known to be concerned with a name under consideration.

B. Such notice shall:

- (i) set forth the name under consideration;
- (ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;
- (iii) identify the substance for which a name is being considered;
- (iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;
- (v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.<sup>1</sup>

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the *Chronicle of the World Health Organization*.<sup>1</sup>

A. Such objection shall:

- (i) identify the person objecting;
- (ii) state his interest in the name;
- (iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international nonproprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international nonproprietary name.

8. In forwarding a recommended international nonproprietary name to Member States under article 7, the Director-General of the World Health Organization shall:

A. request that it be recognized as the nonproprietary name for the substance; and

B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

\* Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.*, 1955, 60, 3) and amended by the Board in resolution EB43.R9 (*Off. Rec. Wld Hlth Org.*, 1969, 173, 10).

<sup>1</sup> The title of this publication was changed to *WHO Chronicle* in January 1959. From 1987 onwards lists of INNs are published in *WHO Drug Information*.

**GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING  
INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES**

1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names in common use.

2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show this relationship. Names that are likely to convey to a patient an anatomical, physiological,

pathological or therapeutic suggestion should be avoided.

*These primary principles are to be implemented by using the following secondary principles*

3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility of devising suitable INN for related substances, belonging to the new group.

4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name, e.g. "oxacillin" and "oxacillin sodium", "ibufenac" and "ibufenac sodium".

5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for different salts or esters of the same active substance should differ

only in respect of the name of the inactive acid or the inactive base.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

7. To facilitate the translation and pronunciation of INN, "f" should be

used instead of "ph", "t" instead of "th", "e" instead of "ae" or "oe", and "i" instead of "y"; the use of the letters "h" and "k" should be avoided.

8. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

9. Group relationship in INN (see Guiding Principle 2) should if possible be shown by using a common stem. The following list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active use.<sup>1</sup> Where a stem is shown without any hyphens it may be used anywhere in the name.

<i>Latin</i>	<i>English</i>	
-acum	-ac	} anti-inflammatory agents of the ibufenac group synthetic polypeptides with a corticotrophin-like action analgesics
-actidum	-actide	
-adolom	-adol	
-adol-	-adol-	
-astum	-ast	} anti-asthmatic, anti-allergic substances not acting primarily as antihistaminics antihistaminics
-astinum	-astine	
-azepamum	-azepam	} substances of the diazepam group $\beta$ -lactamase inhibitors
-bactamum	-bactam	
bol	bol	} steroids, anabolic anti-inflammatory analgesics of the phenylbutazone group
-buzonom	-buzone	
-cain-	-cain-	} antifibrillat substances with local anaesthetic activity local anaesthetics
-cainum	-caine	
cef-	cef-	} antibiotics, derivatives of cefalosporanic acid antibiotics, derivatives of 6-aminopenicillanic acid
-cillinum	-cillin	
-conazolom	-conazole	} systematic antifungal agents of the miconazole group corticosteroids, except those of the prednisolone group
cort	cort	
-dipinum	-dipine	} calcium antagonists of the nifedipine group substances of the clofibrate group
-fibratum	-fibrate	
gest	gest	} steroids, progestogens sulfonamide hypoglycemics
gli-	gli-	
io-	io-	} iodine-containing contrast media quaternary ammonium compounds
-ium	-ium	
-metacinum	-metacin	} anti-inflammatory substances of the indometacin group antibiotics, produced by <i>Streptomyces</i> strains
-mycinum	-mycin	
-nidazolom	-nidazole	} antiprotozoal substances of the metronidazole group $\beta$ -adrenergic blocking agents
-ololum	-olol	
-oxacinum	-oxacin	} antibacterial agents of the nalidix acid group sulpiride derivatives
-pridum	-pride	
-pril(at)um	pril(at)	} angiotensin-converting enzyme inhibitors anti-inflammatory substances of the ibuprofen group
-profenum	-profen	
prost	prost	} prostaglandins hypophyseal hormone release-stimulating peptides
-relinum	-relin	
-terolum	-terol	} bronchodilators, phenethylamine derivates $H_2$ -receptor antagonists
-tidinum	-tidine	
-trexatum	-trexate	} folic acid antagonists spasmodic with a papaverine-like action
-verinum	-verine	
vin-	vin-	} vinca type alkaloids
-vin-	-vin-	

<sup>1</sup> A more extensive listing of stems is contained in the working document Pharm S:Nom 15 which is regularly updated and can be requested from Pharmaceuticals, WHO, Geneva.

**Annex 2**  
**NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES:**  
**TWENTIETH REPORT OF THE WHO EXPERT COMMITTEE**

In its twentieth report<sup>1</sup> the WHO Expert Committee on Nonproprietary Names for Pharmaceutical Substances reviewed the general principles for devising, and the procedures for selecting, international nonproprietary names (INN) in the light of developments in pharmaceutical compounds in recent years. The most significant recent change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or derived from natural products. This practice involves employing a characteristic "stem" indicative of a common property of the members of a group. The reasons for, and the implications of, the change are fully discussed. Also

reported is the intention to change the practice with regard to the nomenclature of individual members of polymeric series.

Other sections of the report concern instructions to be followed by bodies making application for international nonproprietary names, the availability of computer-printed cumulative lists of international nonproprietary names, information supplied by WHO Member States concerning their official use of national or international names for pharmaceutical products, and proposals relative to the withdrawal of international nonproprietary names allocated to substances that are no longer in use.

The official texts relating to the procedures for selecting, and general

guidance for devising, international nonproprietary names are reproduced in two annexes to the report. Other annexes give examples of international nonproprietary names that incorporate selected stems, the most frequently used initial groups of letters in international nonproprietary names, a historical review of the programme of selecting international nonproprietary names, some useful literature references, and a model of the form to be used in all applications for international nonproprietary names.

<sup>1</sup> WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances*. Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4. Price: Sw. fr. 6.-.